Xiaoyong Bao, PhD

Research Project:
Targeting Protein That Regulates SARS-CoV-2 Could Lead to Better COVID-19 Treatments

Grant Awarded:

Emerging Respiratory Pathogen Award

Research Topics:

combination therapies experimental therapeutics
immunology immunotherapy
pathology

Research Diseases:

COVID-19
pneumonia
respiratory viruses

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant illness and death worldwide. New SARS-CoV-2 variants have been shown to evade vaccines and treatments that directly target viruses of the previous generation. This highlights the urgent need to discover therapeutic targets that can lead to effective treatments unaffected by virus mutations. We are researching the role of a protein called exchange protein directly activated by cAMP 1 (EPAC1), a novel host regulator of SARS-CoV-2 infection, in controlling replication of the virus and associated inflammation. The results of this project should provide valuable insights that can aid in developing novel treatments against SARS-CoV-2.

Page last updated: October 7, 2024

Join the Patient & Caregiver Network

How to Help People Quit

10 Tips to Protect Yourself from Unhealthy Air

State of the Air Key Findings

Become an Advocate

Register for a LUNG FORCE Walk

Double Your Gift

Xiaoyong Bao, PhD

2X Your Lifesaving Impact

Make a Donation

Become a Lung Health Insider

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA